Drug Profile
MT 2271
Alternative Names: Influenza virus vaccine quadrivalent - Mitsubishi Tanabe Pharma Corporation; MT-2271; Quadrivalent seasonal influenza VLP vaccine - Medicago; Seasonal influenza vaccine quadrivalent - Medicago; Seasonal influenza virus-like particle (VLP) vaccine - MedicagoLatest Information Update: 07 Dec 2021
Price :
$50
*
At a glance
- Originator Medicago
- Developer Medicago; Mitsubishi Tanabe Pharma Corporation
- Class Influenza virus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Influenza virus infections
Most Recent Events
- 22 Oct 2021 Discontinued - Phase-III for Influenza virus infections (In the elderly, Prevention) in Finland and Germany (IM) (Mitsubishi Tanabe Pharmaceutical's pipeline, October 2021)
- 22 Oct 2021 Discontinued - Phase-III for Influenza virus infections (Prevention, In adults) in Finland and Germany (IM) (Mitsubishi Tanabe Pharmaceutical's pipeline, October 2021)
- 22 Oct 2021 Discontinued - Preregistration for Influenza virus infections (In the elderly, Prevention) in Canada (IM) (Mitsubishi Tanabe Pharmaceutical's pipeline, October 2021)